What's Contrasting Contrast?  by Gaibazzi, Nicola
P
I
R
1120 Correspondence JACC Vol. 60, No. 12, 2012
September 18, 2012:1117–212. Boehringer Ingelheim Pharmaceuticals. Advisory Committee Briefing
Document. Available at: http://www.fda.gov/downloads/Advisory
Committees/CommitteesMeetingMaterials/Drugs/Cardiovascularand
RenalDrugsAdvisoryCommittee/UCM226009.pdf. Accessed March
28, 2012.
3. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the
oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers
and patients undergoing total hip replacement. J Clin Pharmacol
2005;45:555–63.
4. Dahl OE. New oral antithrombotics: focus on dabigatran, an oral,
reversible direct thrombin inhibitor for the prevention and treatment of
venous and arterial thromboembolic disorders. Vasc Health Risk Manag
2012;8:45–57.
5. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and
management of major bleeding complications in patients undergoing
catheter ablation of atrial fibrillation: the impact of periprocedural thera-
peutic international normalized ratio. Circulation 2010;121:2550–6.
6. Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation
under therapeutic warfarin reduces periprocedural complications: evidence
from a meta-analysis. Circ Arrhythm Electrophysiol 2012;5:302–11.
What’s Contrasting Contrast?
I read with interest the recently published paper by Greupner et al.
(1), and would like to comment on the surprising absence of
contrast echocardiography among the tested methods for volume
and ejection fraction measurement.
At least 2 previously published studies, which were not appro-
priately referenced and discussed in the paper, conducted in wider
samples (120 and 50 subjects, respectively), demonstrated that
both 2- and 3-dimensional echocardiograms benefit significantly
from contrast administration in terms of accuracy and reduced
interobserver variability compared with standard echocardiography
and cardiac magnetic resonance, as long as volumes and ejection
fraction measurements are considered (2,3).
Furthermore, the study byHoffmann et al. (2) was amulticenter study,
and demonstrated that the interobserver variability of contrast echocar-
diography (both mean percentage of error and intraclass correlation) for
ejection fraction was even lower than that of cardiac magnetic resonance,
which is usually considered the reference method.
Why was there no testing of echocardiography with contrast,
which is cheap, widely available, and approved for endocardial
border enhancement indication?
A slightly modified old-fashioned ultrasound technique has the
potential to outperform more costly, glittering, and technically
demanding techniques, or at least it should be given a fair chance.
This happens in front of the widespread urge to cut the world
health costs, and a clear and common sense European Union
European Atomic Energy Community directive, which compels
the use of nonradiating diagnostic methods in medicine when they
can be used in substitution of methods using ionizing radiations.
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Reply
We found the comments of Dr. Gaibazzi very thoughtful. We
certainly agree that echocardiography should be the “first line”
technique for evaluation of left ventricular function because it is widely
available, easily done, very cost efficient, and does not require ionizing
radiation. Furthermore, contrast media are a possible way to improve
the diagnostic performance of echocardiography (1,2). However,
there is also evidence that computed tomography (CT) shows better
reproducibility and accuracy than contrast-enhanced (CE) echocardi-
ography (3,4) and may be favored in certain patients (e.g., those with
deformed ventricular anatomy).
To address this issue, we also included 2-dimensional (2D) CE
echocardiography in our study. To stay as close to everyday clinical
practice, we left the decision to administer contrast media to the
cardiologist depending on the quality of the acoustic window for
echocardiography. Only 7 of 36 patients underwent 2D CE
echocardiography. In this, albeit small, subgroup of our study,
there was no significant difference in the Bland-Altman analysis of
ejection fraction (EF) and stroke volume for CT, 2D echocardio-
graphy and 2D CE echocardiography compared with magnetic
resonance imaging (MRI) as the reference standard. We found
significantly smaller end-diastolic volume (EDV) and end-systolic
volume (ESV) in 2D echocardiography and 2D CE echocardio-
graphy compared with MRI as the reference standard (Table 1). How-
ever, only 2D echocardiography showed significantly larger limits of
agreement for EDV than CT. In addition, although there was a trend
toward smaller limits of agreement for 2D CE echocardiography, we
found no significant improvement compared with 2D echocardiography.
Therefore, our small cohort indicates that contrast improves the
accuracy of echocardiography, whereas CT is more accurate than
Left Ventricular Function Parameters inthe 7 Patients Who Underwent CE Echocardiography
Table 1
Left Ventricul r Function Parameters in
the 7 Patients Who Underwent CE Echocardiography
MRI CT 2D Echo 2D CE Echo
EF, % 61.5 5.3 62.7 9.9 61.6 9.9 65.5 4.6
EDV, ml 116.5 29.0 126.0 33.3* 81.4 29.4* 94.2 25.9*
ESV, ml 45.7 16.5 47.4 18.8 31.3 12.0* 32.2 9.4*
SV, ml 70.8 14.3 78.6 25.2 50.1 20.3 62.0 18.4
*p  0.05, Wilcoxon test versus MRI.
CE  contrast enhanced; CT  computed tomography; Echo  echocardiography; EDV 
nd-diastolic volume; EF  ejection fraction; ESV  end-systolic volume; MRI  magnetic
esonance imaging; SV  stroke volume; 2D  two-dimensional.
